MIRM

+ Watchlist + Portfolio

Mirum Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $102.24
52-Week Range: $63.23 – $130.00
Market Cap: $5.92B
P/E (TTM): —
EPS (TTM): -13.38
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -702.97%
Return on Assets: -6.79%
Gross Margin: 81.73%
Operating Margin: -14.81%
Profit Margin: -139.18%
Current Ratio: 2.86
Debt/Equity: —
Total Debt: $762.95M
Free Cash Flow: $76.62M
Revenue Growth: 37.90%
Earnings Growth: —
Enterprise Value: $6.63B

MIRM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$77.06M	$186.37M	$336.89M	$521.31M
Cost of Revenue	$12.37M	$47.04M	$81.64M	$100.24M
Gross Profit	$64.69M	$139.34M	$255.25M	$421.07M
Research & Development	$106.84M	$102.61M	$140.63M	$186.18M
Selling, General & Admin	$89.07M	$145.88M	$202.22M	$257.03M
Operating Expenses	$195.91M	$248.49M	$342.85M	$443.21M
Operating Income	-$131.22M	-$109.15M	-$87.61M	-$22.14M
EBITDA	-$122.85M	-$136.49M	-$48.97M	$17.21M
Pretax Income	-$142.07M	-$162.42M	-$86.91M	-$21.43M
Income Tax	-$6.41M	$991.00K	$1.03M	$1.94M
Net Income	-$135.66M	-$163.41M	-$87.94M	-$23.36M
Diluted EPS	-4.02	-3.94	-1.85	-0.47
Diluted Shares	33.98M	40.89M	47.52M	50.20M

MIRM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$28.00M	$286.33M	$222.50M	$296.68M
Receivables	$23.99M	$67.97M	$78.29M	$123.33M
Inventory	$5.57M	$22.31M	$22.40M	$24.89M
Current Assets	$190.22M	$387.54M	$392.79M	$549.68M
Total Assets	$352.91M	$646.62M	$670.75M	$842.81M
Current Liabilities	$64.73M	$87.06M	$126.55M	$205.80M
Long-Term Debt	—	$306.42M	$308.08M	$309.80M
Total Debt	$2.19M	$308.14M	$317.76M	$319.45M
Total Liabilities	$210.87M	$397.95M	$445.11M	$528.12M
Retained Earnings	-$392.82M	-$556.24M	-$644.18M	-$667.54M
Shareholders' Equity	$142.04M	$248.67M	$225.64M	$314.69M
Working Capital	$125.50M	$300.48M	$266.24M	$343.88M
Net Debt	—	$20.09M	$85.58M	$13.11M

MIRM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$120.14M	-$70.94M	$10.32M	$55.83M
Capital Expenditure	-$278.00K	-$20.11M	-$20.99M	-$954.00K
Free Cash Flow	-$120.41M	-$91.05M	-$10.67M	$54.87M
Depreciation & Amortisation	$3.24M	$10.83M	$23.63M	$24.24M
Stock-Based Compensation	$27.01M	$35.02M	$48.44M	$71.42M
Investing Cash Flow	$7.70M	-$107.20M	-$90.13M	-$23.95M
Financing Cash Flow	$109.09M	$336.60M	$17.70M	$40.14M
Net Change in Cash	-$3.35M	$158.46M	-$62.10M	$72.02M

MIRM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$111.58M	$127.78M	$133.01M	$148.93M	$159.88M
Cost of Revenue	$23.02M	$23.42M	$25.54M	$28.26M	$28.80M
Gross Profit	$88.57M	$104.36M	$107.47M	$120.67M	$131.08M
Research & Development	$41.04M	$46.07M	$42.96M	$51.11M	$97.91M
Selling, General & Admin	$57.71M	$63.29M	$61.91M	$74.13M	$96.33M
Operating Expenses	$98.75M	$109.35M	$104.87M	$125.23M	$194.24M
Operating Income	-$10.18M	-$4.99M	$2.60M	-$4.57M	-$63.16M
EBITDA	-$4.00M	$4.19M	$12.31M	$4.71M	-$779.19M
Pretax Income	-$13.65M	-$5.46M	$2.64M	-$4.96M	-$789.68M
Income Tax	$1.03M	$402.00K	-$262.00K	$767.00K	$475.00K
Net Income	-$14.68M	-$5.86M	$2.90M	-$5.73M	-$790.15M
Diluted EPS	-0.30	-0.12	0.05	-0.11	-13.43
Diluted Shares	48.89M	49.73M	56.99M	51.90M	58.85M

MIRM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$211.82M	$228.12M	$282.02M	$296.68M	$324.91M
Receivables	$95.85M	$106.84M	$107.13M	$123.33M	$133.11M
Inventory	$22.42M	$22.94M	$24.02M	$24.89M	$25.52M
Current Assets	$410.82M	$453.40M	$530.58M	$549.68M	$569.44M
Total Assets	$690.25M	$725.83M	$785.12M	$842.81M	$890.92M
Current Liabilities	$127.58M	$144.80M	$160.36M	$205.80M	$272.82M
Long-Term Debt	$308.51M	$308.93M	$309.37M	$309.80M	$310.25M
Total Debt	$317.16M	$318.90M	$318.76M	$319.45M	$323.78M
Total Liabilities	$456.99M	$470.67M	$493.07M	$528.12M	$648.42M
Retained Earnings	-$658.86M	-$664.72M	-$661.81M	-$667.54M	-$1.46B
Shareholders' Equity	$233.26M	$255.16M	$292.05M	$314.69M	$242.49M
Working Capital	$283.24M	$308.60M	$370.22M	$343.88M	$296.61M
Net Debt	$96.69M	$80.81M	$27.35M	$13.11M	—

MIRM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.96M	$12.04M	$39.68M	$6.07M	-$228.76M
Capital Expenditure	-$41.00K	-$126.00K	-$187.00K	-$600.00K	-$10.66M
Free Cash Flow	-$2.00M	$11.91M	$39.49M	$5.47M	-$239.43M
Depreciation & Amortisation	$6.05M	$6.06M	$6.06M	$6.07M	$6.87M
Stock-Based Compensation	$15.80M	$18.47M	$18.13M	$19.03M	$36.20M
Investing Cash Flow	-$16.13M	-$6.60M	-$2.23M	$1.01M	-$11.57M
Financing Cash Flow	$6.36M	$8.69M	$16.10M	$9.00M	$270.08M
Net Change in Cash	-$11.74M	$14.13M	$53.55M	$16.07M	$29.75M

Market Snapshot

About

Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. The company focuses on cholestatic liver conditions and other orphan hepatic disorders with high unmet medical needs.